Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.95 8,971,479 15:40:38
Bid Price Offer Price High Price Low Price Open Price
1.90 2.00 1.95 1.925 1.95
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.05 -1.12 -0.03 63
Last Trade Time Trade Type Trade Size Trade Price Currency
16:28:56 O 65,057 1.989 GBX

Sareum (SAR) Latest News

More Sareum News
Sareum Investors    Sareum Takeover Rumours

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date Time Title Posts
18/4/202110:06Sareum 2015 5,749
08/1/202118:09SAR - Sareum Holdings drug discovery370
12/10/202012:29Positive Leukaemia Model19
12/10/202012:29Aurora FLT36

Add a New Thread

Sareum (SAR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Sareum trades in real-time

Sareum (SAR) Top Chat Posts

Sareum Daily Update: Sareum Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 1.95p.
Sareum Holdings Plc has a 4 week average price of 1.53p and a 12 week average price of 1.53p.
The 1 year high share price is 3.10p while the 1 year low share price is currently 0.51p.
There are currently 3,255,415,104 shares in issue and the average daily traded volume is 20,225,702 shares. The market capitalisation of Sareum Holdings Plc is £63,480,594.53.
silvergreyhead1: Yeah just come back in from a walk and it's changed now letting me sell but down in price. Anyway hopefully we will get some good news early this month, surely from the news and statistics everyone can see they need therapeutics as well. Hopefully SAR gave one of the answers.
barkboo: CQ - your first paragraph highlights the very point I was making...the accounts would not be delayed because of auditors/lockdown...this has not been a problem with other companies. Sar have delayed to include an important announcement imo. - money always talks!
gordan ghetto: ANA is the best UK cannabis stock Share price 1.1p Only £6.4m mkt cap Fastest growing sector worldwide Will have first mover advantage in UK Same growers as GW Pharma 4 biggest shareholders hold over 50% BOD own 30% Massively undervalued (£6.4m mkt cap) Near term multi bagger on license approval Partners with leading prof , scientists etc Primed for a RTO/ main listing (price driver) Under the radar (most chased MXC,CBX) Looking to bring a product to market Off take agreement in place already Will be producing 200 TONS per year (200,000 kilos) Has the most land out of every cannabis co Fully funded for phase 1 UK medical cannabis growing 20% month Only 584m shares in issue Hardly any available in open market Will apply for a commercial license too Worth getting in on the ground floor imho. hTTps:// hTTps://
cerrito: By chance I ran into this article today covering SAR hxxps:// I was interested to read the following quote The completion of SDC-1801’s pre-clinical work in the coming months is the next milestone to look out for unquote Am I right to be surprised by this wording given that we were told in the December 15th AGM statement that they aimed to file the CTA by the end of this month?
mrsapeslaptop: I would add Froth2 look at posting history. This was the 3rd largest rising biotech stock in 2020 in europe. And they were slagging it off before the rise. On empirical evidence (facts. Share price). How humiliating to be publicly so wrong. Keep an eye out for any other stocks he negs for the next multibagger. Just check their post history. And calculate how much you would have made doing the opposite. Half a million in my case. Effing fool
norma_stitts: I know people bang on about volume but for me the indication is the fact about £0.5m of shares changed hands today. About a year ago an average day; when you factor in both the volume and the share price, we were lucky to see £25k a day of trades. Heck, some days we weren’t even touching £5/10k. Interest is gaining traction. As the saying goes ‘follow the money!’.
cerrito: I have read the q&a from the December meeting which is now up on IMS website. In terms of the newsflow this quarter which will influence the share price, to me the most important will be the submission of the CTA, as covered in question 30. The tenor of this answer is to me less upbeat than what I read from Tim’s comments in the October Results presentation where at about 7minutes 20 seconds, I got the impression that this had been sorted. Do you folks see things differently? It will be interesting to hear what they say on this when they present the interims in March on the basis that they have not filed the CTA by then. I would be pleasantly surprised if we have any developments from Sierra in Q1. I am not sure if news on Aurora will move the share price all that much. That said, I do see it as key. If they file the CTA by end of Q1, and if they get the answer by end of Q2,then it would be very convenient that they have the cash to keep them going till Q3 so that their next fundraising can capitalize on the success of the CTA and that will be helped by having the Aurora money. This is on the basis that as I understand from Tim in one of his presentations that the CTA turnaround is three months. Is that what you understand? On other points, I am not as critical as others on the company’s PR and I thought their reply on this was very realistic.
norma_stitts: Red, it’s from the 26th March RNS about the FLT3 licensing deal; Sareum Holdings plc ("Sareum" or the "Company") Sareum Signs Global Licensing Deal for its FLT3+Aurora Kinase Inhibitor Programme with a China-based Specialty Pharma Company Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that it has entered into an agreement (the "Agreement") with a China-based specialty pharmaceutical company (the "Licensee). Under the terms of the Agreement, the Licensee has been granted an exclusive worldwide licence to develop, manufacture and commercialise certain small molecule inhibitors of FLT3+Aurora kinases including Sareum's lead candidate SAR-20293 (together the "Compounds"), which has shown potential in preclinical models of acute myeloid leukaemia (AML) and other leukaemias. The Licensee is principally engaged in research and development, production and sales of innovative drugs, including oncology drugs, in China and is listed on the main market of the Shanghai Stock Exchange. Under the terms of the Agreement, the Licensee will fund all future development activities in relation to the Compounds and has been granted sole rights to market any resulting products worldwide. Sareum will receive an initial upfront payment of approximately £50,000. A further payment of approximately £0.9 million will be payable to Sareum if certain milestones related to the oral bioavailability of the Compounds are achieved within nine months from the date of the Agreement (the "Development Payment"). Sareum will assign certain patents in respect of the Compounds to the Licensee upon receipt of the Development Payment. The Agreement may be terminated with immediate effect if Sareum does not receive the Development Payment within nine months of the date of the Agreement. Sareum will also be entitled to receive a future milestone payment in the event that an Investigational New Drug or equivalent application is made in China or any other country. Under the Agreement, Sareum is also eligible to receive certain revenues from the commercialisation of the products by the Licensee outside of China. In addition, Sareum would be eligible to receive commercialisation revenues relating to their commercialisation should the Licensee execute an on-licence of the Compounds and resulting products to a third party. Since all research and development expenditure is written off as it occurs, in line with standard industry practise, the Compounds covered by the Agreement are held at nil value on Sareum's balance sheet. Sareum was advised and assisted on this agreement by Cambridge (UK)-based technology brokerage Link China Pharma Solutions. Sareum's CEO, Dr Tim Mitchell, commented: "We are delighted with this important global licensing deal for our FLT3+Aurora inhibitor programme, which could generate significant milestone revenue in the next nine months. We believe the Licensee has the resources and expertise to further advance these molecules through the clinic to commercialisation in China. "With this programme now partnered, we are wholly focused on advancing the development of our proprietary TYK2/JAK1 inhibitors through preclinical studies and look forward to providing updates as material milestones are reached."
andrbea: RMM's post on LSE: RMM3383 Posts: 509 Price: 0.55 No Opinion RE: SynairgenToday 00:12 Potnak/Krone – What we have is a 3 product pipeline (Aurora/737/Tyk2) with multiple sub levels. Two tiers for TYK2 with 1801/2 and a huge range of indications (including various cancers and immune which includes respiratory/Covid). Rather than calculating an absolute value based on what SAR has in terms of a potential share of multiple indications what I’m basing my valuation on is the significantly reduced risk level in terms of SAR and its pipeline getting at least one molecule into licencing territory (or in 737’s case on-licencing). Any acquirer will look at the risk/return. Risk gets reduced in two ways in pharma – data - get to P2 and there’s a lot of data to base a valuation on so the risk is reduced but not completely. Discounting - at the pre-clinical stage there’s a lot less data and therefore much higher risk so to counter this the valuation goes down. Currently 737 is the least risky of all SAR’s assets but we’re not in control. The value for 737 is currently based on potential milestones which could put 3p on the share price overnight if they materialise. For TYK2 getting one indication licensed pre-clinical should add another 3p+ dependent on the size of the upfront. Originally SAR timelined one indication in Q4 2020 but with the current cash pot they now think they could get both 1801 and 1802 away so double that with another 3p. Then there’s Aurora. Get that resolved and another 1p goes into the pot. We’re now looking at 10p but that’s current value not future value. For a buyout you have to agree how many years profits/earnings are being bought and that’s a difficult one to square because it’s both trials and patent dependent. 8 years worth of profits would not be unreasonable for a product that gets to market (SP would be 80p) but the chances that all SAR’s products would get to market are low so discounts come into play and effectively that’s a negotiation. Assume that only 1 product makes it and that’s a 75% discount thus buyout share price = 20p. About a year or so ago I estimated a buyout share price of around 16p (different model). So, the question that might be posed before the next AGM is ‘would you accept somewhere between 10p and 20p as a buy out price now or do you want the BoD to continue down the milestones, clinical path with all the associated risk in the hope that you might get to an 80p or even higher exit?’ Big question. Dividends sound great as long as everything gets to market. Interestingly if you take SNG’s multi bag factor of 35 then the share price for SAR would be 19p. Food for thought. I’d take that! Of course none of the above takes into account ‘Investor fever’, an intangible factor that should be on our side given the interest in biotech but the ‘fickle factor’ is exactly that and as volatile as AIM. GLA LTH’s. All the above IMHO and certainly not to be taken as advice to buy/sell or hold. I'm now off to bed....
twodegrees: Potential strategy in COVID-19 The SARS-Cov-2 pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, in COVID-19. Such a move would require external funding, but could accelerate clinical development timelines and catalyse a substantial increase in value. Meanwhile, the recent £1m fundraising allows Sareum to advance SDC-1801 towards trials for mainstream autoimmune conditions. Sareum intends to make grant applications to explore the activity of SDC-1801 in COVID-19, where the aim would be to reduce the immune system over-reaction that is seen in the later phase of the infection. If such grant applications are awarded, SDC-1801 could join a group of drugs – including a number of JAK inhibitors – that have been fast-tracked into trials for COVID-19 As a dual TYK2/JAK1 inhibitor, SDC-1801 could be more effective and/or better tolerated than these similar compounds in COVID-19. Meanwhile, Sareum has raised £1m via an equity issue that allows it to advance SDC-1801 into clinical trials for autoimmune disease, consistent with its original business plan. While we are not ascribing value to the COVID-19 opportunity at present, we have increased our estimate of the TYK2 assets’ current value to $30-50m. After modest assumptions for R&D spending, we are assigning a fair value for Sareum in the £25–45m range (0.76– 1.38p/share), with the interest in SRA-737 representing upside to the investment case that may be realised in a deal involving the licensee Sierra Oncology. wdt_ID Year ended Revenue (£m) Profit before tax (£m) Earnings per share (p) Dividend per share (p) 1 30 Jun 2018 0.00 -1.70 -0.05 0.00 2 30 Jun 2019 0.00 -1.70 -0.05 0.00 3 30 Jun 2020 0.10 -1.30 -0.04 0.00 4 30 Jun 2021 0.00 -1.40 -0.04 0.00
Sareum share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210419 03:50:54